Predictive Clinical Biomarkers Market worth $14.69 billion by 2030
The report "Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics) -Forecast to 2030" is projected to grow from USD 8.49 billion in 2025 and to reach USD 14.69 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 11.6% during the forecast period.
Browse 708 market data Tables and 56 Figures spread through 506 Pages and in-depth TOC on "Predictive Clinical Biomarkers Market by Product & Service (Consumable, Software), Technology (NGS, PCR), Disease (Cancer, Infectious), Application (Clinical Diagnostics) -Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/predictive-biomarkers-market-97566514.html
The predictive clinical biomarkers market is growing, driven by several key factors, including the rising adoption of targeted therapies and immunotherapies and the integration of biomarkers into clinical trials Design.
The immunoassay segment accounted for the largest share of the predictive clinical biomarkers market, by technology.
By technology, the immunoassay segment accounted for the largest share of the predictive clinical biomarkers market in 2024. Clinical laboratories, cancer centers, and pharmaceutical companies increasingly favor immunoassay platforms because they enable high-throughput, cost-effective measurement of proteins, cytokines, and other circulating markers, making them ideal for routine disease monitoring and for validating prognostic and predictive biomarkers signatures.
In 2024, the personalized medicines segment registered the fastest growth.
Personalized medicine is emerging as the fastest-growing use of predictive clinical biomarkers because doctors can match each patient to the most effective therapy upfront, avoid unnecessary side effects, and adjust treatment as the disease evolves, turning lab results into more precise, individualized care pathways.
North america accounted for the largest regional share in the predictive clinical biomarkers market in 2024.
The predictive clinical biomarkers market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America holds the largest share, supported by a dense network of academic centers, cancer institutes, and commercial labs that have widely adopted NGS testing, liquid biopsies, and companion diagnostics. Favorable reimbursement, flagship government initiatives such as the Cancer Moonshot, and strong pharma–biotech investment in biomarker-driven clinical trials further reinforce North America’s leading position in genomics biomarkers revenues.
Key players in the genomic biomarkers market include Thermo Fisher Scientific Inc. (US), F. QIAGEN (Germany), Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Abbott (US), Pacbio (US), Illumina, Inc. (US)
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Predictive Clinical Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
